Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
- Update on RSV F Vaccine Phase 3 Prepare™ trial for infants via maternal immunization
- Results from Phase 1/2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose flu vaccine
“We look forward to sharing this meaningful information and data from our key vaccine clinical trials with the international infectious disease community next week at the
Details for the two presentations are as follows:
Title: “The RSV F nanoparticle vaccine for infants via maternal immunization in Phase 3: rationale and update”
Date and Time:
Title: “Novavax NanoFlu vaccine induced improved immune responses against homologous and drifted A/H3N2 viruses in older adults compared to egg-based, high-dose, influenza vaccine”
Date and Time:
RSV is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively.1 In the US, RSV is the leading cause of hospitalization of infants.2 Despite the induction of post-infection immunity, repeat infection and lifelong susceptibility to RSV is common.3 Currently, there is no approved RSV vaccine available.
RSV F Vaccine Maternal Immunization Program
Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as infants, young children and older adults, but also in the general population largely because of infection by continuously evolving strains of influenza which can evade the existing protective antibodies in humans. An estimated one million deaths each year are attributed to influenza.4 Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S.,
Nanoflu Phase 1/2 Clinical Trial
About NanoFlu™ and Matrix M™
NanoFlu vaccine is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by
Statements herein relating to the future of
2 Leader S. Pediatr Infect Dis J. 2002 Jul;21(7):629-32
3 PLOS. “How immunity to respiratory syncytial virus develops in childhood, deteriorates in adults.” ScienceDaily.
4 Resolution of the
5 Influenza Vaccines Forecasts. Datamonitor (2013)
Source: Novavax, Inc.